Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Harvard Business School
Fuji
McKinsey
Dow
AstraZeneca
QuintilesIMS
Covington

Generated: December 15, 2018

DrugPatentWatch Database Preview

TRIFERIC Drug Profile

« Back to Dashboard

When do Triferic patents expire, and when can generic versions of Triferic launch?

Triferic is a drug marketed by Rockwell Medical Inc and is included in two NDAs. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

Summary for TRIFERIC
International Patents:11
US Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 28
Clinical Trials: 7
Formulation / Manufacturing:see details
DailyMed Link:TRIFERIC at DailyMed
Drug patent expirations by year for TRIFERIC
Generic Entry Opportunity Date for TRIFERIC
Generic Entry Date for TRIFERIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TRIFERIC

US Patents and Regulatory Information for TRIFERIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate FOR SOLUTION;INTRAVENOUS 208551-001 Apr 25, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-002 Sep 4, 2015 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for TRIFERIC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 206317-001 Jan 23, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Harvard Business School
Fuji
McKinsey
Dow
AstraZeneca
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.